Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 25

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 25
---
 by us in any of our direct or indirect subsidiaries that are also PFICs, each a lower-tier PFIC, and will be subject to similar adverse rules with respect to distributions from, or dispositions of, such lower-tier PFICs, in each case as if such U.S. investor held such shares directly (even if such U.S. investor does not receive the proceeds of such distributions or dispositions directly). We will endeavor to cause any lower-tier PFIC to provide to a U.S. investor the information that may be required to make or maintain a QEF Election with respect to the lower-tier PFIC. However, there can be no assurance we will have timely knowledge of the status of any such lower-tier PFIC.

<div align='center'>15</div>

TABLE OF CONTENTS

U.S. investors should consult their tax advisors regarding our PFIC status for any taxable year and the potential application of the PFIC rules to an investment in our ADSs or ordinary shares including the availability and the advisability of making a QEF Election or a mark-to-market election with respect to us, and the application of the PFIC rules to any of our subsidiaries.

<div align='center'>16</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We will not receive any proceeds from the sale of the ADSs by the Selling Shareholders under this prospectus, but will incur expenses in connection with the registration of these offered securities. However, we could receive up to US$150 million in gross proceeds if the Warrants are exercised in full for cash based on an exercise price of $76.80 per ordinary share. We cannot predict when or if the Warrants will be exercised. It is possible that the Warrants may expire and may never be exercised.

We intend to use the net proceeds from the exercise of Warrants under this prospectus for commercialization preparation, working capital and other general corporate purposes.

The amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of our development and commercialization efforts, the status of and results from our clinical, non- clinical or pre-clinical trials, whether or not we enter into strategic collaborations or partnerships, and our operating costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds from the exercise of the Warrants.

<div align='center'>17</div>

TABLE OF CONTENTS

CAPITALIZATION The following table sets forth our capitalization as of June 30, 2025: • on